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Recombinase-based conditional and reversible
gene regulation via XTR alleles
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Synthetic biological tools that enable precise regulation of gene function within in vivo
systems have enormous potential to discern gene function in diverse physiological settings.
Here we report the development and characterization of a synthetic gene switch that, when
targeted in the mouse germline, enables conditional inactivation, reports gene expression and
allows inducible restoration of the targeted gene. Gene inactivation and reporter expression is
achieved through Cre-mediated stable inversion of an integrated gene-trap reporter, whereas
inducible gene restoration is afforded by Flp-dependent deletion of the inverted gene trap. We
validate our approach by targeting the p53 and Rb genes and establishing cell line and in vivo
cancer model systems, to study the impact of p53 or Rb inactivation and restoration. We term
this allele system XTR, to denote each of the allelic states and the associated expression
patterns of the targeted gene: eXpressed (XTR), Trapped (TR) and Restored (R).
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I
dentifying causal relationships between gene function and the
physiological programmes they control is a central goal of
biological research and an unmet challenge in cancer.
Although loss-of-function mutations in tumour suppressor genes
are the most common type of genetic alteration in cancer,
identifying how these genes function within physiologically
relevant in vivo settings remains difﬁcult. Restoration of tumour
suppressor gene function has the potential to identify relevant
programmes of tumour suppression in physiologically diverse
settings. This strategy rests on the premise that latent tumour
suppressive programmes are poised to react to the reintroduction
of tumour suppressor genes, and that the ensuing changes they
orchestrate will expose relevant mechanisms of tumour suppres-
sion. In addition, experimental restoration of tumour suppressor
genes highlights the potential of future therapies aimed at
restoring tumour suppressive pathways to treat cancer. Several
different approaches have been used to restore endogenous gene
expression in vivo and these have identiﬁed tumour suppression
programmes that are tissue and context speciﬁc1–6. Despite the
power of these approaches, their widespread application to
in vivo biological systems has been constrained by multiple
technological hurdles and limitations inherent to each method
(see Discussion).
Conditional approaches to inactivate gene expression in the
mouse commonly rely on expression of specialized site-speciﬁc
recombinases such as Cre and Flp. These recombinases facilitate
deletion of DNA sequences that are ﬂanked by similarly oriented
DNA elements called loxP or FRT, respectively. Cre and Flp can
also facilitate the reversible inversion of DNA sequences that
intervene inversely oriented loxP or FRT sites. However, the
inherent reversibility of the inversion reaction is often proble-
matic due to the mosaic pattern of DNA rearrangements that
result. To drive reproducible and stable DNA inversions, mutant
loxP and FRT sites have been used to facilitate the permanent
inversion of DNA sequences containing gene traps, to create
conditional alleles in mouse embryonic stem (ES) cells and adult
mice7–10.
Here we developed a synthetic gene switch, XTR, that
uses mutant loxP sites to invert a synthetic ﬂuorescent
reporter trap element to drive conditional inactivation of
endogenous genes. In addition, we engineered the capability to
restore accurate endogenous gene expression via Flp-dependent
deletion of the synthetic gene switch in a temporally controlled
manner. Designed for broad use and compatibility with
established recombinase-based tools, XTR alleles provide a
powerful method to establish causal relationships between
genes and the greater physiological programmes they regulate
in speciﬁc contexts.
Results
XTR allele design. Our goal was to develop a single unifying
allelic system that works in concert with existing genetically
engineered mouse models of human cancer using the site-speciﬁc
DNA recombinases Cre and Flp, and would enable temporally
controlled gene inactivation followed by accurate and inducible
gene restoration (Fig. 1a). To take advantage of the large array
of methods to deliver Cre and the diverse model systems that rely
on Cre-driven cancer initiation, we developed a ‘double-ﬂoxed’
gene trap that can be stably inverted by Cre, to conditionally
inactivate virtually any gene of interest. The gene trap consists of
a strong adenoviral 40 splice acceptor (SA), followed by the
coding sequence for green ﬂuorescent protein (GFP) and the
SV40 polyadenylation transcription termination sequence
(Fig. 1b). We chose this DNA element because of its small
size, ability to report expression from the endogenous host gene
once trapped and its proven ability to recapitulate gene
knockout phenotypes in cells11–16. To enable stable inversion of
the gene trap we oriented inverted pairs of Lox5171 and Lox2722
sites in an alternating manner such that each pair ﬂanked the
gene trap9,17. This double-ﬂoxed organization results in the
permanent inversion of the gene trap after two successive
Cre-mediated recombination reactions (Fig. 1b)7,8. In addition,
we ﬂanked the entire gene trap with FRT sites to enable deletion
of the gene trap by Flp recombinase and restoration of the
targeted gene (Fig. 1b). The GFP reporter feature of the XTR
system requires in-frame splicing from the upstream exon
in instances where XTR is inserted downstream of the
translation initiation site of the host gene. To allow general
applicability, we developed independent XTR allele targeting
vectors with the SA–GFP in each of the three reading frames
(Supplementary Fig. 1).
Targeting and validation of XTR alleles at Rb1 and Trp53. To
validate this system and generate alleles that will be of widespread
use to the cancer biology community, we targeted the XTR
cassette to evolutionarily non-conserved regions of the ﬁrst intron
of the Trp53 and Rb1 genes (p53 and Rb hereafter). Correctly,
targeted ES cells gave rise to multiple independent mouse
lines harbouring XTR alleles (Supplementary Figs 2 and 3). To
validate each feature of the XTR system, we established murine
embryonic ﬁbroblast (MEF) lines from XTR/XTR, XTR/þ and
þ /þ littermates for both Rb and p53. MEF lines were sequen-
tially exposed to Cre and then Flp recombinase via adenoviral
infection or through the tamoxifen-inducible Cre-ER fusion
protein. In both p53XTR/XTR and RbXTR/XTR MEFs, Cre efﬁciently
converted the XTR alleles to the TR conformation and Flp sub-
sequently converted the TR alleles to the R conformation
(Fig. 1c,d). A key feature of the XTR system is the ability of TR
alleles to report host gene expression patterns through GFP
expression, while simultaneously eliminating host gene expres-
sion. After exposing p53XTR/XTR or RbXTR/XTR MEF lines to Cre,
these cells expressed GFP (Fig. 1e). As designed, the pattern of
GFP expression reports the activity of the respective promoters
for each gene: p53TR/TR cells expressed robust levels of GFP after
Cre-mediated recombination, whereas RbTR/TR cells expressed
lower yet detectable levels of GFP. Importantly, the induction of
GFP in both p53TR/TR and RbTR/TRMEFs coincided with a
respective loss of p53 and Rb protein expression (Fig. 1f,g). The
major goal of the XTR system is to allow a previously inactivated
gene to be restored on exposure to Flp recombinase. Infection of
p53TR/TR or RbTR/TR MEFs with adenoviral FlpO (mammalian
codon-optimized Flp) effectively restored p53 and Rb expression
to levels indistinguishable from those in p53XTR/XTR or
RbXTR/XTR MEF lines (Fig. 1f,g).
MEFs from wild-type mice lose proliferative potential after
multiple serial passages and enter into a senescent state18.
Consistent with their normal regulation of p53, p53XTR/XTR MEFs
ceased to divide after an initial proliferative phase and entered
senescence. To determine whether TR alleles phenocopy null
alleles, we converted pre-senescent p53XTR/XTR MEFs to p53TR/TR
MEFs with AdCre. p53TR/TR MEFs bypassed the proliferative
arrest and proliferated indeﬁnitely. Consistent with restoration
of p53 in MEFs using other methods, restoration of p53
expression via AdFlpO treatment in immortalized p53TR/TR
MEF cultures completely arrested cell proliferation, demon-
strating that sustained inactivation of p53 is required for cellular
immortalization of MEFs (Fig. 1h)19. Collectively, these results
demonstrate that the XTR allele allows normal p53 regulation, the
TR allele is equivalent to null and the R allele restores
physiological gene expression.
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RbTR alleles are functionally null. To assess the ability of RbTR
alleles to functionally inactivate Rb, we crossed Meox2-Cre
transgenic mice that express Cre in the germline with RbXTR
animals, to generate RbTR/þ mice20. As Rb is an essential gene,
we would not expect live-born RbTR/TR mice if the TR allele
phenocopied a knockout allele21,22. Indeed, out of 51 pups born
through these crosses, zero RbTR/TR pups were generated, whereas
both Rbþ /þ and RbTR/þ pups were observed at the expected
frequency (Fig. 2a). Analysis of embryonic day 13.5 mice, a time
point before the onset of lethality-causing phenotypes, revealed
the presence of grossly normal RbTR/TR embryos that expressed
GFP. As anticipated, RbTR/TR embryos had twofold higher levels
of GFP than RbTR/þ embryos (Fig. 2b). Taken together, these
analyses suggest that Rb gene function is lost in RbTR/TR mice.
p53TR alleles accelerate Myc-driven lymphomagenesis. Loss of
p53 expression is causally associated with tumour progression in
human cancers and multiple mouse models exist where loss of
p53 exacerbates cancer phenotypes. To determine whether XTR
alleles could be used to functionally inactivate tumour suppressor
genes in diverse tumour models, we crossed the p53XTR allele to
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Figure 1 | XTR alleles facilitate Cre-mediated inactivation and subsequent Flp-dependent restoration of endogenous genes. (a) Cre converts XTR alleles
to the TR allele, thereby inactivating gene function. Flp restores gene function by conversion to R. (b) Schematic of the XTR allele. Cre drives irreversible
inversion of a double-ﬂoxed gene trap consisting of a splice acceptor (SA) enhanced GFP complementary DNA and the polyadenylation transcriptional
terminator sequence (pA). Inversion can proceed either through sequential action of Cre on Lox2272 sites then Lox5171 sites (2272 intermediate) or
Lox5171 then Lox2272 sites (5171 intermediate). Stable inversion accepts splicing from upstream exons in the host gene, reads out GFP expression and then
terminates transcription, leading to functional inactivation of the host gene’s expression. Flp drives deletion of the gene trap (SA-GFP-pA), thereby
restoring normal splicing of the host gene. AdCre and AdCre followed by AdFlpO treatment is indicated (c,d). PCR-based detection of Rb (c) and p53
(d) XTR, TR, R and wild-type (þ ) alleles in MEFs of the indicated genotype. (e) Detection of GFP reporter expression from TR alleles in RbTR/TR and
p53TR/TR MEFs by ﬂow cytometry analysis. Representative of Z3 cell lines. (f) Immunoblot analysis of Rb and GFP expression in RbXTR/XTR MEFs treated
sequentially with AdCre and/or AdFlpO as indicated. b-Tubulin is a loading control. (g) Immunoblot analysis of p53 and GFP expression in p53XTR/XTR MEFs
treated sequentially with AdCre and/or AdFlpO as indicated. Hsp90 is a loading control. (h) 3T3 proliferation assay of p53XTR/XTR MEFs treated
sequentially with AdCre (day 3) then AdFlpO (day 21) as indicated. Representative of two p53XTR/XTR cell lines.
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three different well-characterized cancer models. The Em-Myc
transgenic mouse models Burkitt’s type lymphoma, a B-cell
malignancy driven by high levels of Myc expression from the
immunoglobulin heavy chain enhancer23. Lymphomagenesis in
this model is limited by a p53-dependent apoptotic programme
and animals deﬁcient in one or both copies of p53 develop
aggressive disease within the ﬁrst month of life compared with
4–6 months in p53þ /þ mice24,25. We exploited the conditional
nature of the XTR system, to determine whether somatic
recombination of p53XTR/XTR to p53TR/TR would inactivate p53
expression and lead to rapid onset of lymphoma in Em-Myc
transgenic mice. Em-Myc; p53XTR/XTR;Rosa26CreER/þ and
Em-Myc;p53þ /þ ;Rosa26CreER/þ mice were aged 10–12 weeks
and then treated with a single dose of tamoxifen to activate
CreER. Conversion of p53XTR to p53TR with tamoxifen treatment
led to rapid lymphoma formation with all mice developing
aggressive B-cell malignancies with a median onset of 11.5 days.
In contrast, p53þ /þ mice remained tumour free for prolonged
periods after tamoxifen treatment (Fig. 2c). Lymphomas that
developed in Em-Myc;p53XTR/XTR;Rosa26CreER/þ mice treated
with tamoxifen expressed GFP, indicating conversion of p53XTR
to p53TR and activation of the gene trap. GFP signal was easily
detected by direct ﬂuorescence microscopy on necropsy,
highlighting the potential utility of the XTR system to track
and isolate tumour cells (Fig. 2d).
p53TR alleles phenocopy p53ﬂox alleles in cancer models. The
XTR system was designed to be compatible with cancer models
where additional Cre-dependent alleles are required for tumour
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Figure 2 | RbTR and p53TR alleles phenocopy conventional ﬂoxed and knockout alleles. (a) Number of Rbþ /þ , RbTR/þ and RbTR/TR newborn pubs
observed in RbTR/þX RbTR/þ crosses. Percentage and number indicated, w2¼ 12.4, df¼ 2, P¼ 104. (b) GFP detection in RbTR/TR, RbTR/þ and Rbþ /þ
embryonic day 13.5 embryos. (c) Kaplan–Meier analysis of lymphoma onset in tamoxifen-treated Em-Myc; p53XTR/XTR; Rosa26CreER/þ and Em-Myc; p53þ /þ ;
Rosa26CreER/þmice; P¼0.0017, log-rank (Mantel–Cox) test. (d) GFP imaging of lymphoma cells in an Em-Myc; p53XTR/XTR; Rosa26CreER/þ mouse after
lymphoma onset. (e) Initiation of sarcomas by intramuscular (IM) injection of AdCre into the hindlimb of KrasLSL-G12D/þ ; p53XTR/XTR(KPXTR/XTR) and
KrasLSL-G12D/þ ; p53ﬂox/ﬂox(KPﬂox/ﬂox) mice. (f) Kaplan–Meier analysis of sarcoma onset in KPXTR/XTR and KPﬂox/ﬂox mice. (g) Representative sarcomas from
KPXTR/XTR (n¼ 11) and KPﬂox/ﬂox (n¼ 3) mice shown by whole-mount bright-ﬁeld and ﬂuorescent (GFP) microscopy and also (haematoxylin and eosin)
staining of histological sections. (h) Initiation of lung adenocarcinoma by inhalation of AdCre in KPXTR/XTR (n¼8) and KPﬂox/ﬂox (n¼ 10) mice. (i) Kaplan–
Meier survival analysis in KPXTR/XTR and KPﬂox/ﬂox mice after inhalation of AdCre. (j) Representative lungs from KPXTR/XTR and KPﬂox/ﬂox mice shown by
whole-mount bright-ﬁeld and ﬂuorescent (GFP) microscopy and H&E staining of histological sections. (k,l,m) Comparison of tumour burden (% of lung
area), tumour number and tumour grade between KPXTR/XTR and KPﬂox/ﬂoxmice. Scale bars, 25 mm.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms9783
4 NATURE COMMUNICATIONS | 6:8783 |DOI: 10.1038/ncomms9783 | www.nature.com/naturecommunications
& 2015 Macmillan Publishers Limited. All rights reserved.
formation. To assess this potential, we crossed p53XTR mice to
KrasLSL-G12D/þ mice, which harbour a conditional oncogenic
KrasG12D allele whose expression is dependent on exposure to
Cre26,27. KrasLSL-G12D/þ and traditional p53ﬂox alleles have been
used to model several human tumour types including soft tissue
sarcoma and lung adenocarcinoma28,29. In each of these models,
Cre-expressing viruses are delivered directly to the site of tumour
formation by direct injection into the muscle to generate sarcomas
or inhalation to generate lung adenocarcinoma. To determine
whether p53XTR could work in concert with the KrasLSL-G12D/þ
allele and phenocopy p53ﬂox alleles in these tumour models, we
initiated tumours in KrasLSL-G12D/þp53XTR/XTR(KPXTR/XTR) and
KrasLSL-G12D/þ ;p53ﬂox/ﬂox(KPﬂox/ﬂox) mice and compared the
frequency of tumour initiation and degree of histological
progression in models of sarcoma and lung adenocarcinoma
(Fig. 2e–m). Intramuscular injection of AdCre initiated sarcomas
in KPXTR/XTR and KPﬂox/ﬂoxmice with similar penetrance
and median time to sarcoma onset (Fig. 2f). KPXTR/XTR
and KPﬂox/ﬂox sarcomas were histologically similar, containing
high-grade spindle cell lesions with atypical nuclei and frequent
mitotic ﬁgures, and consistent with conversion to p53TR/TR
sarcomas arising in KPXTR/XTR mice were GFP positive (Fig. 2g).
Inhalation of AdCre into KPXTR/XTR and KPﬂox/ﬂox mice
resulted in robust lung tumour formation that led to declines in
survival with similar rates in each cohort. KPXTR/XTR mice had
tumours with bright GFP signal consistent with conversion to
p53TR/TR (Fig. 2j). Tumour number, grade and the extent of
tumour burden in KPﬂox/ﬂox and KPXTR/XTR mice were also
indistinguishable (Fig. 2k–m). Taken together, these data
demonstrate that XTR is a robust method to inactivate tumour
suppressor gene function in diverse tumour types with similar
effectiveness to conventional ﬂoxed alleles. In addition, the bright
GFP signal from the p53TR/TR allele affords a convenient method
to identify, isolate and track tumour cells.
FlpO-ER facilities efﬁcient restoration of p53TR alleles. Robust
methods to temporally regulate Flp activity in vivo are critical to
realize the full potential of the XTR system. Based on our success
using oestrogen receptor (ER) fusions to Cre recombinase in
regulating loxP-directed recombination events in vivo2, we
generated KPXTR/XTR;Rosa26FlpO-ER/þ mice that ubiquitously
express a tamoxifen-inducible FlpO-ER fusion30. KPXTR/XTR;
Rosa26FlpO-ER/þ MEFs were treated with AdCre to recombine
p53XTR/XTR to p53TR/TR and monitored by ﬂow cytometry for
GFP expression. After 3 days, nearly all of the AdCre-treated cells
were GFP positive as expected (Fig. 3a). On replating, we treated
cells with 4-hydroxytamoxifen to activate FlpO-ER activity and
monitored GFP expression by ﬂow cytometry. Consistent with
the long half-life of GFP, at the ﬁrst passage GFP expression was
reduced ﬁvefold in all cells and by the second passage GFP levels
had diminished to background levels (Fig. 3a). Consistent with
cooperative effects of Kras and p53 mutations to drive
transformation, KPTR/TR;Rosa26FlpO-ER/þ MEFs rapidly formed
tumours after subcutaneous transplantation in nude mice.
Importantly, tamoxifen treatment of mice bearing KPTR/TR;
Rosa26FlpO-ER/þ tumours resulted in rapid loss in growth
potential but had no effect on KPﬂox/ﬂox tumours (Fig. 3b).
To assess the capabilities of FlpO-ER to regulate tumour
suppressor gene restoration in the context of an autochthonous
cancer model, we initiated tumours in the lungs of KPXTR/XTR;
Rosa26FlpO-ER/þ mice by inhalation of AdCre. Initially, we
derived cell lines from individual KPTR/TR;Rosa26FlpO-ER/þ
tumours. In vitro administration of 4-hydroxytamoxifen
led to robust induction of p53 and the p53 target gene p21,
consistent with FlpO-ER-mediated conversion of p53TR/TR to
p53R/R(Fig. 3c). Importantly, tamoxifen treatment of KPXTR/XTR;
Rosa26FlpO-ER/þ mice 13 weeks post tumour initiation also lead
to efﬁcient conversion of p53TR/TR to p53R/R. Tamoxifen
treatment lead to upregulation of p53 and p21, and a concomitant
loss of GFP speciﬁcally in KPTR/TR;Rosa26FlpO-ER/þ but not
KPTR/TR;Rosa26þ /þ tumours (Fig. 3d). In addition, direct
ﬂuorescence microscopy of harvested lungs or immunohistolo-
gical analyses of lung tumour sections revealed that KPTR/TR;
Rosa26þ /þ control tumours displayed multiple GFP-positive
tumours in the lung, suggesting that they maintained
p53TR/TR alleles. In contrast, tamoxifen treatment of KPTR/TR;
Rosa26FlpO-ER/þ tumour-bearing mice resulted in tumours
that had dim or undetectable GFP levels, indicating efﬁcient
conversion to p53R/R alleles (Fig. 3e).
Discussion
Restoration of tumour suppressor gene function in cancer cells
in vivo has proven to be a powerful means to identify context-
speciﬁc programmes of tumour suppression. However, the
widespread practice of restoring gene function in established
tumours within their natural setting has been greatly limited by
previous approaches that are incompatible with speciﬁc genes of
interest or by strategies that require multiple technically
challenging steps to implementation1–5,31.
We and others have used genetically engineered alleles in
which a loxP-ﬂanked transcription/translation stop cassette
(loxP-STOP-loxP; LSL) is inserted into the ﬁrst intron of a gene
of interest1,2. An LSL allele is a null allele until Cre-mediated
recombination deletes the STOP cassette, thus allowing normal
expression of the targeted genes. For example, the p53LSL allele is
a functionally null allele of p53 and p53LSL/LSL mice develop
spontaneous lymphomas and sarcomas at the same frequency and
rate as p53 KO mice1. Initially, p53LSL/LSL mice were used to
study the consequences of p53 restoration in T-cell lymphomas
and soft tissue sarcomas that naturally arise in p53-deﬁcient
mice1. Most genetically engineered mouse cancer models rely on
Cre to activate or inactivate genes of interest, but because LSL
approaches require Cre for gene restoration they are not
compatible with these existing models. Because of this major
limitation, we made use of a lung cancer model (KrasLA2/þ )
where KrasG12D is activated spontaneously due to a stochastic
recombination event32. These mice develop lung adeno-
carcinomas with 100% penetrance at an early age. This afforded
us the opportunity to generate KrasLA2/þ ;p53LSL/LSL mice and to
restore p53 in these early-to-moderate stage lung cancers2.
Performing this restoration in large cohorts of mice was
frustrating, owing to the mortality associated with the frequent
and rapid development of sarcomas and lymphomas in
p53-deﬁcient mice. Extensive ageing of the mice was not
possible and we were unable to assess the effects of p53
restoration on the most clinically relevant advanced stages of
primary lung tumours and metastases.
The most critical limitation of the LSL system is that LSL alleles
cause germline deﬁciency. Thus, LSL alleles cannot be used to
study genes that are required for embryonic development.
Unfortunately, the vast majority of tumour suppressor genes are
embryonic lethal (for example, Rb1, Pten, Apc, Nf1, Nf2, Ptc, Vhl,
Smad4, Atr, Smarca4, Arid1a, Snf5, Nkx2-1, Nkx3-1, Tsc1, Tsc2
and so on), thus leaving very few tumour suppressor genes with
which to use this system (for example, p53, Cdkn2a and Atm).
This fact, together with its incompatibility with other Cre-based
systems, has severely limited the utility of this approach.
Fusion of an ER fragment to proteins may, in some instances,
allow for tamoxifen-dependent activity of the fused protein. In
the limited cases where this has proven effective, it has been a
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robust method. A p53ERTam knock-in allele has been used to
model p53 restoration in Myc-induced lymphomas and in
KrasG12D-induced lung adenocarcinomas3,4. Although, unlike
the LSL approach, the ER-fusion alleles are compatible with
Cre-based cancer models, ER fusions are still limited to non-
essential genes, as mice with homozygous knock-in would still be
expected to recapitulate the embryonic lethality of null mice. In
addition, not all proteins will tolerate carboxy and/or amino-
terminal fusions with the ER and there can be concern of
unknown alterations in function of the ER fusion protein. Finally,
this approach is limited to proteins that carry out their functions
in the nucleus, as the mechanism of induction is based on
tamoxifen-induced nuclear translocation of the fusion protein.
Regulatable small hairpin RNA (shRNA) is a very different
method that overcomes several of the limitations associated with
LSL and ER fusion-based approaches. However, the techniques
involved are challenging and, to date, the generation of
regulatable RNA interference transgenic mice has been employed
by few laboratories. This approach has been used to regulate the
expression of three tumour suppressor genes (Apc, Pten and p53)
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Figure 3 | Tamoxifen-regulated FlpO-ER efﬁciently restores p53TR alleles to p53Rin vitro and in vivo. (a) GFP detection by ﬂow cytometry analysis of
KPXTR/XTR; Rosa26FlpO-ER/þ MEFs. Untreated (p53XTR/XTR: solid grey), AdCre treated (p53TR/TR: solid green), tamoxifen-treated cells previously untreated
(p53R*/R*: open black trace) or previously AdCre-treated (p53R/R: open green trace). R*, direct conversion of p53XTR to p53R. (b) Analysis of transformation
potential of KPXTR/XTR; Rosa26FlpO-ER/þ MEFs after in vitro AdCre treatment followed by subcutaneous engraftment into nude mice. Tumour growth
monitored by caliper measurements at the indicated times. Tamoxifen was administered on day 0, 1 and 2 to all mice. Representative of two cell lines
(n¼4). (c) Immunoblot analysis of lysates from KPTR/TR; Rosa26FlpO-ER/þ lung tumour-derived cell lines 24 h after addition of 4-hydroxytamoxifen
(4-OHT) or vehicle control. (d) Immunoblot analysis of lysates from micro-dissected lung tumours 7 days after tamoxifen delivery. Immune precipitation of
p53 was required before western blotting for detection. (e) Microscopic analysis of lung tumours derived from KPXTR/XTR; Rosa26FlpO-ER/þ and KPXTR/XTR;
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in relevant cancer models5,6,31,33,34. To effectuate potent
knockdown of the target gene and recreate phenotypes
equivalent to null alleles, multiple specialized techniques, mouse
strains and ES cell lines are required35. The success of the
regulatable shRNA to recapitulate phenotypes associated with
gene loss requires the ability to generate a sufﬁciently potent
shRNA. Screening of dozens of shRNAs is therefore required and
specialized protocols to ascertain whether an shRNA is likely to
be effective as a single-copy integrated transgene is necessary35,36.
Despite this, potent shRNAs have been identiﬁed that
approximate null alleles in certain experimental systems5,31,37,38.
Off-target effects associated with shRNA expression are also
potentially problematic39. High expression of a heterologous
shRNA could obscure biological readouts by knocking down the
expression of unintended messenger RNA targets or by
overwhelming the RNA interference processing machinery to
such an extent that naturally expressed micro RNAs are not
normally produced40–42. Each of these technical issues may have
profound consequences on the biology of cells in question that
will have an impact on data interpretation.
Currently, regulatable shRNA strategies rely on tet-based
systems which limits their functionality within other systems
that also utilize tet-regulated transgenes. For example, multiple
cancer models rely on tet-inducible oncogenes to drive tumour
formation and these models rely on continual expression of the
oncogenic driver to maintain the cancer43–46. Although the
regulated shRNA can be easily added into this approach to
ascertain the added effect of target gene knockdown, the ability to
cleanly determine the effect of target gene restoration is not
possible due to the simultaneous loss of oncogene expression on
doxycyclin removal.
The simplicity and functionality of the XTR allele system offers
several signiﬁcant advantages over existing strategies, to inter-
rogate gene function in the mouse. Similar to conventional
approaches to create conditional alleles in the mouse, XTR
integration relies on gene targeting in ES cells. Creation of XTR
alleles uses the same methods that are standard protocols in
academic and commercial ES cell/transgenic mouse facilities and
thus requires no specialized technical hurdles. As outlined in
Supplementary Fig. 3, generation of XTR alleles requires a
neoXTR allele intermediate that necessitates secondary selection
of either ES cell clones or pups that lost the FRT-Neo-FRT. For
p53 and Rb, this was achieved by either electroporation with
Flp-expressing plasmids or by crossing with germline
Flp-expressing mice47. Further use of the XTR system at other
loci will be necessary to determine whether locus-dependent
effects exist that could limit this strategy. CRISPR-based
approaches to generate conditional alleles by directly injecting
zygotes with modiﬁed XTR vectors lacking the FRT-Neo-FRT
cassette could obviate the need for this step48,49.
XTR combines three separate tools into one discrete genetic
element to conditionally inactivate a gene of interest, accurately
report host gene expression once inactivated and facilitate precise
gene restoration in an inducible manner. Bringing these tools
together into one strategy offers unparalleled functionality to a
single genetically engineered allele. With the increased function-
ality to mark gene inactivation and report accurate gene
expression levels of the targeted gene, as well as the ability to
rescue gene function, XTR is positioned to greatly expand current
capabilities to interrogate gene function within in vivo systems.
Thus far, our experience targeting XTR to p53 and Rb loci suggest
a ‘plug and play’ simplicity that abrogates the need for
development, testing and optimization that is associated with
ER fusion and regulatable shRNA strategies. However, targeting
of additional loci will be required to afﬁrm the generalizable
nature of the XTR approach with respect to preserving proper
host gene regulation and robustness of gene inhibition. Although
the XTR system would not be compatible with the few examples
of Flp-dependent alleles that exist50,51, its seamless integration
into the numerous Cre-based model systems available should
facilitate its widespread utility. Similar to most conditional
approaches to inactivate gene function in the mouse, XTR
alleles require specialized methods or mouse strains to deliver Cre
recombinase to speciﬁc cell types of interest. Our data suggest
that either promoter-speciﬁc transgenes or viral based approaches
to deliver Cre to tissues of interest is a robust strategy to
inactivate genes of interest in the mouse with XTR. Finally,
restoration of gene function using XTR alleles requires strategies
to regulate Flp activity. As demonstrated, we used a tamoxifen-
inducible Rosa26FlpO-ER allele that is widely expressed and
therefore suitable for a broad range of applications using the
XTR system30. However, additional strategies to regulate FlpO
may augment the utility of the XTR system in specialized
scenarios.
Here we have targeted the XTR cassette to two important
tumour suppressor genes to address cancer-relevant questions.
However, we envision XTR as a powerful approach to investigate
gene function in diverse biological settings to gain important
insight into mechanisms at the tissue, cellular or molecular level.
In addition, XTR alleles have the potential to model therapeutic
interventions in disease settings, where temporarily inactivating a
putative drug target through the genetic means intrinsic to XTR
could predict efﬁcacy or identify unforeseen complications of
future therapies. More broadly, the ability to restore gene
function using the XTR system offers a major opportunity in
conditional genetic methods to facilitate the widespread applica-
tion of in vivo gene restoration approaches.
Methods
Creation of base targeting vectors. The XTR allele requires targeting to the
desired gene loci, to carry out inducible gene trapping via splice acceptance from
upstream exons; therefore, pNeoXTR plasmids were created to accept splicing from
each of the three reading frames (Supplementary Fig. 1; pNeoXTR f0 (Addgene
#69157), pNeoXTR f1 (Addgene #69158) and pNeoXTR f2 (Addgene #69159)).
Components were assembled from pL451 (Addgene #22687), pFLIP-FF9 (a gift
from Patrick Stern) and pSA-GFP-pA11 (gift from Jan Carette). Alternative reading
frames were established by Quickchange method (Agilent) following the
manufacturer’s instructions. Full sequence of each targeting plasmid is available at
Addgene. Targeting arms were generated by PCR and cloned into base targeting
vectors. Ampliﬁcation of the p53 left arm was accomplished with forward primer
50-tggcgcgccggatcccagcactactgtggttaag-30 and reverse primer 50-ttgcggccgcagaggtttg
agtacaaccagggctg-3. Ampliﬁcation of the p53 right targeting arm was accomplished
with forward primer 50-gtgttaattaacgagtctattgcctttcccagccaac-30 and reverse primer
50-ctgcagccaaaggtccagttacagg-30. Ampliﬁcation of the Rb left arm was accomplished
with forward primer 50-cacggcgcgccgtcaaacagctatgaccatg-30 and reverse primer
50-ccagcgatcgcctcgagaacttaatgatggg-30 . Ampliﬁcation of the Rb right arm was
accomplished with forward primer 50-gtggttaattaaggctcgag-30 and reverse primer
50-gtgttaattaaaaagggatgcaaatagaagg-30 .
ES cell culturing and electroporation. Targeting constructs were linearized and
electroporated independently into F1 C57BL/6  129S4 hybrid v6.5 ES cells (gift
from Rudolph Jaenisch) using standard conditions. Neomycin (300 mgml 1
G418)-resistant colonies were isolated, expanded and screened by PCR and
Southern blotting. Correctly targeted clones were either directly injected into
C57BL/6J blastocysts or ﬁrst electroporated with supercoiled pCAGGS-FLPe (gift
from R. Jaenisch) and plated, to generate subclones. ES cell subclones lacking the
NeoR cassette after FLP recombination were then injected into C57BL/6J blas-
tocysts. Both strategies yielded several high-percentage chimeras and the estab-
lishment of the mouse lines.
Identiﬁcation of targeted ES clones. PCR was used to screen for probable
targeted clones for both p53 and Rb NeoXTR alleles. Reactions spanning the left
targeting arm for p53NeoXTR-targeted clones identiﬁed positive clones with
primers 50-ttcaagagacggagaaagggcg-30 and 50-tggatgtggaatgtgtgcgag-30 . These were
subsequently screened via Southern blotting. PCR screening strategies for Rb were
not successful and failed to detect even those subsequently identiﬁed by Southern
blotting. For Southern blotting, genomic DNA was digested overnight at 37 C with
20Units of each restriction enzyme. The next day, another 10Units were added
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and incubated at 37 C for an additional 4–6 h. DNA fragments were resolved
on 0.7% tris-acetate-EDTA gels at low voltage overnight, stained with ethidium
bromide, depurinated, denatured and neutralized before transfer to Hybond XL
membranes. Ultraviolet cross-linked DNA was hybridized with radioactive probes
suspended in Express Hyb solution (Clontech) as per the manufacturer’s instruc-
tions. Radiolabelled probes were generated by random primer methods using
PrimeIT II Kits (Agilent) and puriﬁed with Quick Spin Columns (Roche). DNA
probes were generated by PCR of mouse genomic DNA. Rb 50-probe was ampliﬁed
with 50-attaagttctcgattcctcag-30 and 50-tgccaggcggacccgactttg-30 primers. The p53
30-probe was ampliﬁed with 50-atagtgggaaccttctgggacg-30 and 50-cagtggaggagcacctg
tcttatg-30 primers. The GFP probe was generated using pSA-GFP-pA as a template
with 50-atggtgagcaagggcgagga-30 and 50-ttacttgtacagctcgtcca-30 primers. Genomic
DNA from ES cell clones following Flpe electroporation was screened by PCR with
the following primers to identify a 528-bp product (RbXTR) or a 587-bp product
(p53XTR): p53 50-caactgttctacctcaagagcc-30  50-taaaaaacctcccacacctcccc-30 and
Rb 50-tgttgttattgtcagcactag-30  50-TAAAAAACCTCCCACACCTCCCC-30 .
Germline deletion of NeoR. p53neoXTR/þ and RbneoXTR/þ mice were crossed to
Rosa26FlpeR/þ mice. p53neoXTR/þ ; Rosa26FlpeR/þ and RbneoXTR/þ ; Rosa26FlpeR/þ
pups were found to contain all possible alleles after Flp reactions (neoXTR, XTR
and R), and were therefore always considered to be mosaic. p53neoXTR/þ ;
Rosa26FlpeR/þ and RbneoXTR/þ ; Rosa26FlpeR/þ mice were subsequently crossed to
wild-type mice and pups that lost the Rosa26FlpeR allele were screened for retention
of XTR and loss of NeoR. See also Supplementary Fig. 3.
Generation and analysis of MEFs. MEFs were generated by timed matings from
E13.5 to E15.5 embryos. Adenoviral infections to express Cre or FlpO recombi-
nases (purchased from Gene Transfer Vector Core at the University of Iowa) were
carried out on sub-conﬂuent cultures using 107–108 viral particles in 6- or 10-cm
dishes. Quantiﬁcation of GFP in MEFs was performed on an LSR II cytometer (BD
Biosciences) at the PennFlow Core. Proliferation assays were carried out in 3T3
format counting and replating 3 105 cells every 3 days in 6-cm dishes. Genotypes
of MEFs were analysed via three-primer PCR reactions using puriﬁed genomic
DNA as a template to detect XTR, TR, R and WT alleles. Primers used for Trp53
were as follows: (1) 50-cttggagacatagccacactg-30 , (2) 50-caactgttctacctcaagagcc-30
and (3) 50-cttgaagaagatggtgcg-30 . Primers used for Rb1 were as follows: (1) 50-tgtt
gttattgtcagcactag-30, (2) 50-ggcagaggcagtaaaacagagagc-30 and (3) 50-cttgaagaagatg
gtgcg-30 .
Immunodetection in cultured cells. Cells were lysed in RIPA buffer and resolved
on NuPage BT gels and then transferred to polyvinylidene diﬂuoride (Millipore).
Blottings were probed with the following antibodies: p53 (Novocastra IMX25,
western, 1:500) or Santa Cruz (FL-393, IP 1 mg), Rb (Santa Cruz, C-15, 1:500), p21
(Santa Cruz, F-5, 1:500), GFP (Cell Signaling Technologies, #2956, 1:1,000), Hsp90
(BD Transduction Labs, Clone 68, 1:1,000), b-Tubulin (Cell Signaling Technolo-
gies, #2146 1:5,000), Actin (Sigma, A2066, 1:1,000). Immunoprecipitation was
carried out in RIPA buffer with standard techniques using Protein G beads.
4-Hydroxytamoxifen dissolved in ethanol was administered once at the time of cell
plating at a ﬁnal concentration of 500 nM. AdCre or AdFlpO (5 107 pfu) was
purchased from the University of Iowa Gene Vector Core and administered to
adherent cells at the indicated times. Full versions of blots are shown in
Supplementary Fig. 4.
Tumour-derived cell lines. Tumours were excised from the lungs of mice using
dissecting stereo microscopy, dissociated with Collagenase IV and trypsin for
30–60min, then quenched with fetal bovine serum, washed in Hank’s balanced salt
solution, then cultured in high glucose-containing DMEM supplemented with 10%
fetal bovine serum and antibiotics at 37 C and 5% CO2 until cell line establishment
(B2–4 weeks).
Animal studies and treatments. All animal experiments were carried out under
strict compliance with Institutional Animal Care and Use Committee at either MIT
or Penn. for KrasLSL-G12D (ref. 26), p53ﬂox/ﬂox (ref. 52), Rosa26FlpeR (ref. 47),
Rosa26FlpO-ER (ref. 30) and Meox2-Cre20 mice have been described. Sarcoma and
lung adenocarcinoma inductions were carried out as described29,53. Tumour
grading was performed at the PennVet Comparative Pathology Core using
established tumour-grading schemes28,29. Tamoxifen treatment was performed on
3 consecutive days via oral gavage of 200ml of a 20mgml 1 solution dissolved in
90% sterile corn oil and 10% ethanol.
Histology and microscopy. Fluorescent signals from tumours were imaged with
either the IVIS Spectrum (Caliper Life Sciences) or a ﬂuorescence stereo dissection
microscope (Leica). Tissues were dissected into 10% Neutral buffered formalin
and ﬁxed 16–20 h at 4 C before being dehydrated in a graded alcohol series.
Parafﬁn-embedded histological sections were produced at the Abramson Family
Cancer Research Institute Histopathology Core as 4 mm sections before staining.
Immunostaining was carried out after citrate-based antigen retrieval with a-GFP
antibody (Abcam ab13970, 1:1,000) and ﬂuorescent secondary detection (Thermo
Fisher, a-Chicken Alexa Fluor 594, 1:200). Microscopy was performed on a Leica
DMI6000B inverted light and ﬂuorescent microscope.
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